Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
Helicobacter Pylori Infection
About this trial
This is an interventional treatment trial for Helicobacter Pylori Infection focused on measuring Helicobacter pylori infection
Eligibility Criteria
Inclusion Criteria:
- Consecutive H. pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis
Exclusion Criteria:
- previous H. pylori-eradication therapy
- ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 weeks
- patients with allergic history to the medications used
- patients with previous gastric surgery
- the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
- pregnant women
Sites / Locations
- Kaohsiung Veterans General Hospital
- Kaohsiung Veterans General Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
7-day quadruple therapy
10-day sequential therapy
7-day standard triple therapy
pantoprazole 40 mg twice daily for 7 days, clarithromycin 500 mg twice daily for 7 days, amoxicillin 1 g twice daily for 7 days, metronidazole 500 mg twice daily for 7 days
pantoprazole 40 mg twice daily for 5 days and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily for 5 days, clarithromycin 500 mg twice daily for 5 days, metronidazole 500 mg twice daily for 5 days.
pantoprazole 40 mg twice daily for 7 days, clarithromycin 500 mg twice daily for 7 days, amoxicillin 1 g twice daily for 7 days.